StemCentrx is a biotechnology company focused on identifying and targeting cancer stem cells to develop novel therapies for solid tumors. Its lead program was rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting DLL3, developed for small cell lung cancer (SCLC) and other DLL3-expressing tumors. Founded in 2008 by Brian Slingerland and Scott J. Dylla, the company was acquired by AbbVie in May 2016 in a deal valued at approximately $5.8 billion upfront plus up to $4 billion in contingent milestone payments.
Stemcentrx has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2008
Total Funding
$517M
4 rounds
Latest Valuation
$5B
August 2015
Total raised $517M across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series G
Date
August 2015
Amount
$250M
Valuation
$5B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| August 2015 | Series G | $250M | $5B | Fidelity Investments, Sequoia Capital |
| May 2014 | Series F (or later) | $200M | — | Sequoia Capital |
| 2012 | Series D | $42M | $0.3B | Founders Fund |
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.
Entry · Series D
$0.3B
Jan 2012
Stemcentrx today
$5B
Aug 2015 · latest mark
Stemcentrx multiple
16.7x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Brian Slingerland
Co-Founder & CEO
Scott J. Dylla
Co-Founder & Chief Scientific Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Seagen
Oncology biotech focused on antibody-drug conjugates (ADCs); pioneer of ADC therapies, acquired by Pfizer in 2023.
ImmunoGen
Developer of antibody-drug conjugates for cancer treatment; acquired by AbbVie in 2024.
OncoMed Pharmaceuticals
Biotech developing therapeutics targeting cancer stem cells and tumor-initiating cells; acquired by Mereo BioPharma in 2019.
Verastem Oncology
Oncology company originally founded around cancer stem cell biology, now developing FAK and PI3K inhibitors.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.